Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial

ÖZAKBAŞ, SERKAN; Cinar, Bilge; Kosehasanogullari, Gorkem; Kahraman, Turhan; Oz, DİDEM; Kursun, Behice

doi:10.1016/j.clineuro.2017.06.016

Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial

Atıf İçin Kopyala

ÖZAKBAŞ S., Cinar B. P., Kosehasanogullari G., Kahraman T., Oz D., Kursun B. B.

CLINICAL NEUROLOGY AND NEUROSURGERY, cilt.160, ss.69-72, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 160
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.clineuro.2017.06.016
Dergi Adı: CLINICAL NEUROLOGY AND NEUROSURGERY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.69-72
Anahtar Kelimeler: Relapsing remitting multiple sclerosis, Pulse methylprednisolone, Expanded disease status scale, Disability, DISABILITY STATUS SCALE, MS
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives: Multiple sclerosis is usually clinically characterized by repeated subacute relapses followed by remissions. Corticosteroids are used for relapses, and this treatment has been shown to increase the speed of recovery from these. We aimed to evaluate the efficacy and safety of pulsed methylprednisolone given every month as an add-on therapy to interferon beta or glatiramer acetate in patients with relapsing-remitting multiple sclerosis.